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I 
Abstract 
Determining the binding affinity and potency in vitro is one of the significant steps 
that can give a clue for a new candidate drug during the drug discovery process. 
Thermofluor is a method used in measuring binding affinity (Kd) of protein-ligands 
interaction through determining the change in thermal denaturation temperature of 
protein using real time PCR (RT-PCR). Kinetic analysis assay is used to screen a 
library of compounds to calculate their potencies (IC50) and inhibition constants (Ki) 
and it can be performed by spectrophotometer technique. In this study, we used 
bovine carbonic anhydrase II (BCA II) enzyme, and four of its inhibitors as a model 
to compare drug affinities, which were determined either by Fluorescence Thermal 
Shift Assay (FTSA) using Sypro Orange dye or kinetic assay using 4-Nitrophenyl 
acetate as a substrate to measure the nonphysiologically esterase activity of CA. The 
inhibitors studied were Methazolamide, Brinzolamide, Dorzolamide HCl and 
Mafenide HCl.  The Kd values were determined to be 5.4±0.085 µM, 1.2±0.44 µM, 
2.08±0.63 µM, and IC50 values were 0.148±0.024 µM 0.129±0.015 µM 0.092±0.01 
µM 1.715±0.16 µM whereas the Ki  values were 4±0.55 nM, 3.5±0.5 nM, 2.5±0.5 nM 
and 46.5±6.5 nM for Methazolamide, Brinzolamide, Dorzolamide HCl and Mafenide 
HCl, respectively. The potencies (IC50) of the inhibitors were10-50 fold lower than 
that of the Kd values. In addition, Kd values were higher compared to Ki values. 
Therefore, kinetic analysis is a more sensitive technique and requires a lower amount 
of the enzyme to measure drug affinity than FTSA. 
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Background: Literature Review 
 
Drug discovery 
The drug discovery process takes about 12-15 years, and more than 1 billion 
dollars to come up with any new candidate drug (Fig. 1). It may take many years to 
build up a body of supporting evidence before selecting a target for a costly drug 
discovery program. Many challenges are present in drug discovery and 
pharmaceutical industry, such as target identification, hit to lead optimization and 
evaluation of drug candidates (Hughes, Rees, Kalindjian, & Philpott, 2011).. 
The hit to lead to process is a valuable technique for distinguishing drug 
candidates. Determining the binding affinity and potency in vitro, is one of the hit to 
lead optimization steps that can give a clue for the candidate drug (Wang, Dong, & 
Sheng, 2019). Creating of methods for rapid screening of inhibitors of specific 
enzyme from compound library is one of the main challenges in drug discovery, 
especially for new targets where the goal is to study and recognize their potential 




Figure 1: Drug discovery process. FDA, Food and Drug Administration; IND, 
Investigational New Drug; NDA, New Drug Application (Hughes et al., 2011). 
 
Universal and valid drug discovery assay technique are desired in order to get 
ahead with the latest developments in combinatorial chemistry and genomics-based 
target production (Pantoliano et al., 2001).Enzymatic assays (e.g. Fluorescence or 
absorbance spectroscopy) are commonly used in measuring the potencies of 
compounds in laboratories. While binding assay such as Fluorescence Thermal shift 
Assay (FTSA) is used to measure the compound affinity. Many compounds that are 
assumed to be potential drugs in treating human diseases, are firstly known through 
studying their binding properties like affinity and potency (FDA, 2003). 
 
Enzymatic assay (kinetic analysis): 
 Enzymatic assays play critical roles in determining the reaction rate, binding 
affinity, catalytic constant, and inhibition rate as well as screening library of 




             One of the major assays is used to estimate Vmax (the maximum velocity of 
the reaction) and KM (Michaelis-Menten constant), which is the substrate 
concentration at half of V max (Eq. 1) (Choi, Rempala, & Kim, 2017). Where the rate 
of the reaction is measured in time course by monitoring the absorbance of the 
product release or the substrate consumption over period of time 
(
(Boeckx, Hertog, 




                                                                           Eq. 1 
Where [S] is the substrate constant; Vmax is the maximal velocity and Km is the 
Michaelis constant which is the substrate concentration of Vmax/2 
IC50 Assay: 
Dose response relationship is displayed by fitting the response against the log 
of the inhibitor concentration through the application of the equation of Four-
Parameter Logistic Function (Eq. 2), (Krohn & Link, 2003). 
𝒚 = 𝑩𝒐𝒕𝒕𝒐𝒎 +
𝑻𝒐𝒑−𝑩𝒐𝒕𝒕𝒐𝒎
𝟏+𝟏𝟎 𝒍𝒐𝒈𝑰𝑪𝟓𝟎−𝒍𝒐𝒈𝒙 ∗𝑯𝒊𝒍𝒍𝑺𝒍𝒐𝒑𝒆
                                                            Eq. 2                                                                  
Where y is: response, x: log of inhibitor concentration, Top and Bottom: plateaus in 
same unit as y, same log unit as x, Hillslope: slop factor or hill slop (unitless). 
High throughput screening assays are mainly used to examine enzyme activity 
and inhibitor efficacy. A total inhibitor concentration that decreases enzyme activity 
by 50% (IC50) is the most used pharmacokinetic measure of a drug's efficacy and 
potency. It is a quantitative measure that indicates the concentration of a drug or 
substance that is required to inhibit a specific biological activity by a half (Aykul & 
Martinez-Hackert, 2016).  
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Inhibition constant Ki: 
Inhibition constant (Ki) is a guide of how potent an inhibitor is, and it is the 
concentration of the inhibitor desired to produce half maximum inhibition. For 
competitive inhibitors It can be calculated by Cheng-Prusoff equation (Eq. 3) 
(Lazareno & Birdsall, 1993).  
𝐾𝑖 =  
𝐼𝐶50
1+ 𝑆 /𝐾𝑚




Binding affinity is the strength of the binding interaction between protein and 
its ligands (like inhibitors or activators). It is generally estimated by the binding 
affinity constant also known as equilibrium dissociation constant (Kd). The smaller 
the Kd value, the greater the binding affinity of the ligand for its target(Pollard, 2010) 
      There are multiple methods available for detection of dissociation constant 
(Kd)value of protein-ligand interactions. Such as, Surface Plasmon Resonance (SPR) 
which is an approach that requires transfer of electromagnetic energy to electrons in a 
thin layer of metal (e.g. Gold) in contact with a solution.  
Fluorescence Polarization (FP)is another method used; it measures the change 
in the rate of the rotation of a fluorophore which can be detected by alteration in 
polarization. This method depends on the binding of a fluorescent ligand to a protein 
which causes the ligand to rotate more slowly. Isothermal Titration Calorimetry 
(ITC): This method quantifies the heat produced from a chemical reaction in solution. 
Because almost all enzyme-ligand reactions release or consume heat, and no 
fluorescent labels of the enzyme or ligand are required. ITC is the only known method 
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capable to immediately measure the enthalpy, ΔH, of a ligand binding to a 
protein(Mittermaier & Meneses, 2013).
 
Thermofluor also known as Thermal shift assay (TSA) or Differential 
Scanning Fluorimetry (DSF), measures the change in thermal denaturation 
temperature of a protein under different conditions (e.g., pH, salts, additives, drugs or 
mutations).And this method requires only RT-PCR machine, data can easily be 
analyzed as many protocols are available to quantify the data from TSA to rapidly 
demonstrate Kd values and predict the binding affinity of protein-ligand interaction 
(Mittermaier & Meneses, 2013). 
FTSA (Fluorescence Thermal Shift Assay) monitors thermal unfolding of 
proteins in the presence of a fluorescent dye which is highly fluorescent in non-polar 
environment, such as the hydrophobic sites on unfolded proteins, compared to 
aqueous solution where the fluorescence is quenched (Fig. 2). Usually, TSA can be 
applied for variety of enzymes where it is run by a real-time PCR instrument (Niesen, 
Berglund, & Vedadi, 2007).  
 
This assay is used for detection of protein-ligand interactions. After the ligand 
binds to the folded protein, it will stabilize it. As a result of that, it will increase the 
melting temperature (Tm), which is needed to unfold the protein. In consequence, this 
will result in shifts in unfolding curves and Tm to give (∆Tm), and analyzing these data 
gives the value of the dissociation constant (Kd) which determines the binding affinity 





Figure 2: The two-state transition curve. In the first state, the fluorescence intensity 
increases upon enzyme unfolding, where the hydrophobic region becomes exposed to 
the dye allowing it to bind with the enzyme. After reaching the plateau, in the second 
state, the fluorescence intensity begins to decrease as the denatured enzyme-dye 




Carbonic Anhydrase (CA) Overview: 
Carbonic Anhydrase is an enzyme which requires zinc ion to function as a 
Lewis acid in the reaction mechanism at the active site, where it can be coordinated to 
three histidine and a hydroxide ion to catalyze the reversible hydration of carbon 
dioxide (CO2) and dehydration of bicarbonate ion (HCO3
-
) (Eq. 4) (Iqbal, Nisar-Ur-
Rahman, & Iqbal, 2014; Iyer, Barrese, Parakh, Parker, & Tripp, 2006). 
             CO2 + H2O⇌HCO3
-
 + H




       CAs are present in plant and animal tissues. There are several classes of 
CAs; α, β, γ, δ and δ. α- class is found in bacteria and mammals, and about 16 
different mammalian isozymes such as CA I, CA II, CA III, CA IV …etc. were 
described (Taslimi et al., 2016). CAs I and II are abundantly found in red blood cells 
of mammals where CA II is one of the most known isozymes in α- class that was 
discovered in 1933 by Meldrum and Rougton (Meldrum & Roughton, 1933). Bovine 
carbonic anhydrase II (BCA II) is similar to the human one(Iqbal et al., 2014) and it is 
a cytosolic, single-chain, approximately 30 KDa enzyme.  In addition, CAs are found 
in mammals, and can be divided in four subgroups according to their localization; 
cytosolic, mitochondrial, membrane bound with extracellular domains or secreted 
(Krishnamurthy et al., 2008a).  
Carbonic anhydrase enzyme is involved in different physiological processes, 
such as pH homeostasis, calcification, respiration, vision, gas exchange and bone 
resorption (Krishnamurthy et al., 2008a). These functions make it a target for many 
drugs that function as CA inhibitors. CA anhydrase inhibitors are used in many 
conditions such as; glaucoma, cancer, epilepsy, obesity, heart failure and intercranial 
hypertension. Examples include, sulfonamides which are the most common inhibitors 
class of CA (Iqbal et al., 2014).  Additionally, methazolamide and brinzolamide 
which help in reduction of elevated intraocular pressure in patients with open-angle 
glaucoma or ocular hypertension, dorzolamide is used in the treatment of acute or 
chronic vascular hypertension and mafenide used as antibacterial agent (Brunton, 
L.B., Lazo, J.S., & Parker, 2005). 
         CA is an excellent model for studying enzyme kinetics for small 
molecule ligands due to several reasons. These include the fact that it does not contain 
disulfide bonds, it is monomeric, stable, it can be easily purified, it has known amino 
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acid sequences, and the mechanism of its catalytic activity is known.  Additionally ,  
the mechanism of inhibition of it is well understood and it is easy to evaluate the 
binding of ligands by different high throughput assays (Krishnamurthy et al., 2008a).   
     The assays that study the CA activity can be generally subdivided into 
main groups. One method includes CO2 consumption detection, where carbonic 
dioxide and carbonate act as substrates for estimation of CA activity. Also,  stopped-
flow assay which estimates the CA activity by monitoring the pH changes of 
dehydration of HCO
3- 
to CO2 or the reverse reaction (Krishnamurthy et al., 2008a). In 
1965, Pocker and Stone established another type of assay to measure the CA activity, 
and a spectrophotometric technique for verifying the esterase activity of CA by 
catalyzing the non-phycological hydrolysis of esters like hydrolysis of 4-Nitrophenyl 
acetate (4-NPA). The product (nitrophenolate) ionizes to give yellow nitrophenolate 
anion which can be detected at 400 nm by using UV-spectrophotometer (y. pocker, 
1965).  
 
Can we use FTSA to study the binding affinity?  
 
Generally, Thermofluor (FTSA) is easy, fast, and inexpensive. It does not 
require creating new assays with each new target and can be  used also for any 
unknown compound method to measure the binding affinity of the compounds other 
than the known enzymatic assays, these advantages could be an improvement of drug 
discovery field (Matulis, Kranz, Salemme, & Todd, 2005). 
Recently, FTSA method is used in studying the binding affinity Kd of the hit 
compounds as qualitative measurement, and there are many approaches and protocols 
9 
 
applied in order to concede this method for quantitative measurement. Therefore, 
enzymatic assay has been conducted for a variety of enzymes with different ligands to 
determine IC50 values and compared them with the binding affinity constant (Kd) 
values that is obtained from thermal shift assay.  
Lo et al., (2004) compared the binding affinities measured by FTSA and ITC 
with the IC50 values, which were measured by enzymatic assay, using β-site amyloid 
precursor protein-cleaving enzyme 1 (BACE1). They concluded that Kd values from 
FTSA are correlated to the Kds that were obtained from ITC and IC50 from enzymatic 
assay. In addition, they suggested that candidate hits can be determined based on ∆Tm 
values, if FTSA can be run at appropriate compound concentrations in connection to 
their dissociation constants. 
Bai et al., (2019) proposed and established new approach for analyzing FTSA 
data using experimental data for maltose binding protein (MBP) and maltose, and for 
two carbonic anhydrase isoforms with four of their inhibitors. Enzymatic assay was 
applied to determine the inhibition constant (Ki) to obtain an independent measure of 
the interaction between the enzyme and each of the inhibitors. They concluded that 
there is a corelation between the binding constant and the inhibition constant, 
especially for potency range between uM to mM range.  
Smirnovienė, Smirnovas, & Matulis, (2017) studied the importance of 
inhibition and binding assays using carbonic anhydrase by applying enzymatic 
stopped-flow CO2 assay and FTSA, respectively. Kd of picomolar was successfully 
measured by FTSA, which is promising in drug discovery world. As a result, a 
correlation between IC50 and Kd is observed. Moreover, they suggested that the 
combination between the two methods can give a higher quality and precise data.  
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In this study, carbonic anhydrase enzyme was used as a model with four of its 
known competitive inhibitors (methazolamide, brinzolamide, dorzolamide HCl and 
mafenide HCL) to perform kinetic assays and FTSA using uncomplicated and 
straightforward protocol(Iyer et al., 2006; Laubach, A. E., Wang, E., & Anderson, 
2015). Then comparison was made between the potency (IC50), inhibition constant 
(Ki) and binding affinity (Kd) to demonstrate if FTSA is suitable and practical for 
screening of inhibitors and identifying hit compound. In addition, optimization of the 
FTSA technique was done to build up an effective and easily use method to determine 
drug affinity.  
 
Materials and Methods 
 
Carbonic Anhydrase concentration determination: 
Stock solutions of each of methazolamide(Sigma-Aldrich, St. Louis, MO), 
brinzolamide (Selleck Chemicals, Houston, TX) and mafenide HCl (Selleck 
Chemicals, Houston, TX) were prepared in 100% DMSO, and Dorzolamide HCl 
(Selleck Chemicals, Houston, TX) was prepared in distilled water to make 10 mM 
solution. 2 mg/ml of bovine CAII (Sigma-Aldrich, St. Louis, MO) was prepared using 
buff er (Tris-HCl, pH 8.2). 20X solution of SYPRO Orange dye (Invitrogen™ 
Molecular Probes™, 5,000X Concentrate in DMSO) were prepared in (Tris-HCl, pH 
8.2). 
To monitor the enzyme unfolding a total of 20 µL of mixture contains 2 µl of 
SYPRO Orange dye (2X final concentration), 2 µl of Bovine CAII (0.0008-0.1) 
mg/ml, and 16 µl of Tris-HCl buffer were mixed on 96-well PCR plate. A18 µL of 
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buffer and 2 µL of Sypro Orange dye was used as control. Then the assay plate 
covered with a sheet of optically clear adhesive. Main measurements were carried out 
in duplicate. Then fluorescence was measured from 25℃ for 2 minutes then 1℃/min to 
95℃ (excitation, 450-490 nm; detection, 560-580 nm.) Then, FTSAs were performed 
on a StepOnePlus Real-Time PCR System (ThermoFisher, Waltham, Massachusetts, 
USA.). Then data was fitted using Excel 2013 (Microsoft, Redmond, WA) program.   
Initially, Sypro Orange dye was compared with GloMelt™ dye (Sybr Green 
dye manufactured by Biotium Inc. Fremont, CA). A total of 20 µl mixture was used in 
the assay with different concentrations of the enzyme (0.0008-0.1) mg/ml, with either 
2 µl of 2X of Sypro Orange or 2X of Sybr Green, and 16 µl Buffer. 2 µl of dye and 18 
µl of buffer were added together as a control. Then fluorescence was measured from 
25℃ for 2 minutes then 1℃/min to 95℃ (excitation, 450-490 nm; detection, 560-580 
nm.) by RT-PCR.  
The signal of Sypro Orange was found to be stronger (Fig. 3). A possible 
explanation for this finding is the difference in the sensitivity of RT-PCR machine. In 
addition, Sypro Orange has many advantages compare to Sybr Green dye; it is 




Figure 3: Comparison of fluorescence signal with Sypro Orange dye and Sybr Green 
dye at 0.1 mg/ml BCA II concentration. 
 
Determination of kd of the inhibitors 
 
FTSA was run using a total of 20 µl mixture, which contained 2 µl of Sypro 
Orange dye (2X final concentration), 12 µl of Tris-HCl buffer, 2 µl of BCA II  (0.1 
mg/ml in assay) and 4 µL of different concentrations (0.23 – 100 µM) of either 
methazolamide, brinzolamide or dorzolamide HCl, and (0.46-200 µM) of Mafenide 
HCL were mixed in 96-well plate. As a positive control, 2 µl of Carbonic anhydrase, 
2 µL of the dye and 16 µl of buffer were added together. 1% DMSO was used as a 
negative control. Then the assay plate covered with a sheet of optically clear adhesive 
and fluorescence was measured from 25℃ for 2 minutes and then 1℃/min to 95℃ 
(excitation, 450-490 nm; detection, 560-580 nm.). FTSAs were performed on a 


























Sybr Green Sypro Orange
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determination were performed using the GraphPad Prism 8software (GraphPad 
software. Inc) and applied Boltzmann Sigmoidal curve equation (Eq.5).  
 






                                                       Eq. 5                      
Where Y: fluorescence intensity; X: temperature; Bottom: baseline fluorescence at 
low temperature; Top: maximal fluorescence at the top; Slope: the steepness of the 
curve; and Tm: melting temperature of the enzyme. 
Then the date was analyzed by GraphPad Prism 8 software using the single 
site ligand binding equation (Eq. 6) (Vivoli, Novak, Littlechild, & Harmer, 2014):  
𝒀 = 𝑩 + ( 𝑻 − 𝑩 ∗ (𝟏 − ((𝑷 − 𝑲𝒅 − 𝑿 +
 (  𝑷+𝑿+𝑲𝒅 𝟐 − 𝟒∗𝑷∗𝑿 )) 
𝟐∗𝑷
                 Eq. 6 
Where P: protein concentration. Kd:  dissociation constant (has the same unit as 
P). T: melting temperature at high inhibitor concentration; B: melting 




Determination of the Enzyme concentration 
The catalytic activity of BCA II was monitored by the hydrolysis of the 
nonphysiologically ester (4-NPA) (Sigma-Aldrich, St. Louis, MO). The products of 
the hydrolysis reaction are acetate and nitrophenolate, which ionizes to give a bright 
yellow anion that is detected by measuring its absorbance at 400 nm with a Synergy™ 
2 spectrophotometer (Biotek instruments Winooski, VT) using 96-well plates.For 
initial screens, 200 µl of assay solution containing 10 µl of (0.0008-0.1) mg/ml of 
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BCA II, 10 µl of 4-NPA and 180 µl of Tris-HCl buffer were dispensed into 96-well 
plates which were incubated for about 20-30 minutes at room temperature. As a 
control 10 µl of the enzyme and 190 µl of the buffer were mixed. Then, the 
absorbance was read at 400 nm. The data were plotted on Excel to choose the enzyme 
concentration that is suitable to use in the IC50 detection 
. 
Esterase activity Assay 
Calculation of Vmax and Km: 
The assay was performed by adding 10 ul of different substrate concentrations 
of 4-NPA (0.00195-0.25) mM. In addition, 10 ul of 6 ng/ul BCA (II) and 180 ul of 
Tris-HCl buffer were mixed in 96-well plate. Then the absorbance was read at 400 nm 
using the spectrophotometer.  Michaelis Menten equation (Eq. 1) was applied and the 
curve was plotted by GraphPad Prism 8. To find out Km value and Vmax (ƹ = 21,000 
M-1cm-1) (Krishnamurthy et al., 2008b). 
Calculation of Ki: 
To determine the inhibition constants (Ki) values for each one of the inhibitors, 
Cheng-Prusoff equation (Eq. 3) was applied. 
 
Calculation of IC50: 
The assays were performed by adding10 µl of each methazolamide, 
brinzolamide or dorzolamide HCl (0.039-5) µM final concentration or 10 µl of 
mafenide HCl (0.078-10 µM), 10 ul of 6 ng/ul of the enzyme, 10 µl of 4-NPA 
substrate (0.25 nM final concentration) and 170 µl of the buffer. Less than 1% DMSO 
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was used as a control. The normalized data were then fit to the 4-parameter nonlinear 
sigmoidal dose-response model using GraphPad Prism version 8 software to obtain 
the IC50 and Hill slope (Eq. 2) (Iyer et al., 2006). 
 
Results  
The thermal unfolding of different concentrations of BCA II was monitored by 
RT-PCR thermocycler which generated curves that showed a two-state transition (Fig. 
2). In the first state, the fluorescence intensity increases upon enzyme unfolding, 
where the hydrophobic region becomes exposed to the SYPRO Orange dye allowing 
it to bind with the enzyme. After reaching the plateau, in the second state, the 
fluorescence intensity begins to decrease as the denatured enzyme-dye complex starts 
to aggregate. Comparing the fluorescence intensity of different concentrations of BCA 
II showed that the 3.33 µM concentration of the enzyme gives the highest read of the 
fluorescence intensity (Fig. 4), so it was chosen to be used in the FTSA experiment to 
measure the binding affinity (Kd) of the inhibitors. Determination of protein stability 
and its melting temperature were obtained by FTSA, followed by data analysis using 






Figure 4: Thermal unfolding of different concentrations of BCA II (3.33 µM, 1.67 
µM, 0.83 µM and 0.42 µM) monitored by 2X SYPRO Orange each in triplicate. 
Normalization was done by using Boltzmann equation. 
 
      
The Melting temperatures Tm (the midpoint of the first state of fluorescence 
transition) were calculated using (Eq.3). As the inhibitor binds at the hydrophobic 
region of the unfolding enzyme, the melting temperature Tm increases. The calculated 
Tm of the enzyme was higher in the presence of the inhibitor and positively correlated 
to the inhibitor concentration (Figures 5A, 6A, and 7A) show the shifts in melting 
temperature curves of methazolamide, brinzolamide and dorzolamide HCl, 
respectively.  
The stability of the enzyme increases as the inhibitor concentration is 
increased.  Binding affinity constants (Kds) were calculated using (Eq. 4) for the four 
inhibitors and they were 5.4±0.085 µM, 1.2±0.44 µM, 2.08±0.63 µM for 
methazolamide, brinzolamide and dorzolamide, respectively. (Figures 5B, 6B and 7B) 
show ∆Tm values which are significant and increased with the inhibitor concentration. 
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∆Tm is large for the higher affinity inhibitor and decreased when the affinity 
decreases. Kd value of mafenide HCl was hard to detect and it was difficult to observe 
the Tm shifts where ∆Tm was less than 2 ℃. This could be due to the low solubility of 


















Figure 5 (A)Thermal shift curves of unfolding transition of 3.33 µM CA II in the 
presence of 100 µM, 44.5 µM, 19.8 µM, 8.8 µM and 0 µM of Methazolamide. Data 
fit to Boltzmann equation gave midpoint Tm of 71˚C, 70˚C, 69.5˚C, 68.5˚C and 65˚C, 
respectively, (R
2 












































Figure 6(A)Thermal shift curves of unfolding transition of 3.33 µM CA II in the 
presence of 100 µM, 44.5 µM, 19.8 µM, 8.8 µM and 0 µM of Brinzolamide. Data fit 
to Boltzmann equation gave midpoint Tm of 77˚C, 76.7˚C, 75.6˚C, 74˚C and 64˚C, 
respectively, (R
2 



















































Figure 7: (A)Thermal shift curves of unfolding transition of 3.33 µM CA II in the 
presence of 100 µM, 44.5 µM, 19.8 µM, 8.8 µM and 0 µM of Dorzolamide HCl. Data 
fit to Boltzmann equation gave midpoint Tm of 76˚C, 74˚C, 73˚C, 72˚C and 64˚C, 
respectively, (R
2 
≥ 0.9). (B) ∆Tm s are ranging between (0 – 12.6) ˚C. n = 3 




















































Figure 8: Thermal shift curves of unfolding transition of 3.33 µM BCA II in the 
presence of 200 µM, 133 µM, 12 µM and 0 µM of Mafenide HCl. Data fit to 
Boltzmann equation gave midpoint Tm of 66.8˚C, 66.7˚C, 66˚C and 65˚C, 
respectively, (R
2 








































Vmax and Km results: 
  
The Km value determined from the initial velocity data was found to be 10 ± 3 µM, 
which is an average of three trials and the error is the standard deviation of the three 
trials.  












Figure 9: Plot of Michaels-Menten equation. Velocity vs N-NPA concentration was 
fitted to the Michaelis-Menten equation (Eqn. 1) to determine the Km value for CA. 
The fit for CA II-catalyzed reaction was done using the program GraphPad Prsim ® 
version 8. The reactions were performed in triplicate and the average of the three Km 
values was 10 ± 3 µM. 4-NPA concentrations (0.00195-0.25) mM and 6 ng/µl of 
BCA II. 
 
Ki valuer were calculated using Cheng-Prusoff equation for competitive inhibitors 
(methazolamide, brinzolamide, dorzolamide HCl and mafenide HCl), where Km = 
10±3 µM and substrate concentration was 0.25 mM(Laubach, A. E., Wang, E., & 
Anderson, 2015;Iyer et al., 2006): 
𝐾𝑖 =  
𝐼𝐶50
1+ 𝑆 /𝐾𝑚
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Ki values were 4±0.55 nM, 3.5±0.5 nM, 2.5±0.5 nM and 46.5±6.5 nM for 
methazolamide, brinzolamide, dorzolamide HCl and mafenide HCl, respectively. The 
reactions were performed in triplicate n=3.  
IC50 results  
 
The results of the half maximal inhibitory concentration (IC50) for 
methazolamide, brinzolamide, dorzolamide HCl and mafenide HCl were 0.148±0.024 
µM, 0.129±0.015 µM, 0.092±0.01 µM and 1.715±0.16 µM, respectively (Fig.10).  
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Figure 10: IC50s values were determined by fitting a dose-response (four parameters) 
curve of the inhibition (%) to the data, using the GraphPad Prism program. (R
2 
≥ 0.9) 





The affinity constants (Kd) were about 10-50-fold higher than the potencies 
and they were were not close in the magnitudes to those of Ki values (Table 1). 
Table 2: Values of Kd, IC50 and Ki 








Methazolamide 5.4±0.085 0.148±0.024 0.004±0.00055  
Brinzolamide 1.2±0.44 0.129±0.015 0.0035±0.0005 
Dorzolamide HCl 2.08±0.63 0.092±0.01 0.0025±0.0005 




For binding assays and enzymatic assays, sample standard deviation for each 
condition was calculated using the STDEV.S function in Microsoft Excel and Error 
ranges for fitted IC50, Ki and Kd values were defined as 95% confidence intervals. 
 
Discussion 
The primary purpose of this study was to examine the ability of 
applying FTSA in determination of hit to lead compound in research study by 
comparing it with two of the commonly used traditional kinetic analysis 
methods by measuring the affinities of four known inhibitors of CA. 
25 
 
FTSA technique has number of advantages such as:  it is easy to use, 
inexpensive, the RT-PCR machine used to run the assay is readily available in 
most of the laboratories and industries, it doesn’t depend on previous 
knowledge of the value of the affinity or potency to modify the conditions of 
the reaction, and it can be used as a primary detection method for the 
qualitative measurement of the binding affinity of unknown compounds which 
is one of the initial steps in the drug discovery process.  
The findings of this study for (methazolamide, brinzolamide and 
dorzolamide HCl and mafenide HCl) indicate that the Kd values obtained by 
FTSA were about 10-50 fold higher than that of the IC50 values that were 
obtained from the enzymatic assay. In addition, Kd values were higher   
compared to Ki values. 
A commonly cited explanation for the difference of these measured 
values is that the reaction was conducted under different temperatures. FTSA 
uses a  high temperature that can probably reach about 77 ℃ Tm compared to 
the room temperature (25℃) that is used when running the IC50 assay 
(Redhead, Satchell, McCarthy, Pollack, & Unitt, 2017). 
The need for a high concentration of the enzyme in this approach to get 
the proper fluorescence intensity is required to observe the melting 
temperature shifts between different concentrations of the inhibitor. Thereby 
making it hard to measure the precise Kd value for a potent drug (Vivoli et al., 
2014).  
Some reports in the literature concluded that there is a correlation 
between Kd values and IC50 values, which were measured by FTSA and 
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traditional enzymatic assay, respectively (Bai et al., 2019; Lo et al., 2004; 
Smirnovienė et al., 2017). 
The discrepancy between the values of the Kd using the approach of 
FTAS which is used in this study as well as the values that were published 
using other approaches of FTSA could be due to consideration of the enthalpy 
values (∆H) of the reaction in their FTSA approach, which can help measuring 
low Kds values. Especially, for high potent inhibitors (Smirnovienė et al., 
2017).  
Another finding in this study is that it was difficult to observe the shift 
in Tm for mafenide HCl (low potency drug) that could be explained by low 
solubility at high concentration. For some ligands such concentration may be 
too high due to limited solubility. If the solubility is below the expected Kd, 
then the determination is impracticable and hard to obtain. (Cimmperman & 
Matulis, 2011) (Matulis et al., 2005). 
Limitations of the FTSA include that some ligands may interfere with 
the dye or interact covalently with the unfolded enzyme. Enzyme folding 
could be reversable and can cause aggregation at higher temperature (Bai et 
al., 2019).The binding constant calculated by FTSA is measured at high 
temperatures and not in the  physiological temperature, and this point should 
be taken in consideration when FTSA is compare with enzymatic assay. 
However, estimation of  lower binding constants Kd is applicable if the Van’t 
Hoff enthalpy  (∆Hᶱ) of binding is known (Matulis et al., 2005). To determine 
thermal shift of weakly binding compounds, their concentration should be 
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more than the expected Kd. This could be an issue because they may have 
limited solubility at high concentration. As a result, it creates a  hard 
observation of the thermal shift (Cimmperman & Matulis, 2011).  
  Despite these limitations, FTSA has several advantages like its 
simplicity in use for identification of candidate hits, also its general 
applicability to large different target proteins. The IC50 values do not 
recognize the mechanism of action. Consequently, various unrelated 
compounds may exhibit the same activity due to interactions at different sites. 
Moreover, FTSA can identify mechanistic information such as stoichiometry 
and differentiate covalent and noncovalent interactions. (Matulis et al., 2005) 
Conclusion 
The findings of this study which compared drug affinities determined by 
enzymatic analysis and FTSA showed that the potencies (IC50) of the potent drugs 
were 10-50 folds lower than that of the Kd values. In addition, Kd values were higher 
compared to Ki values. The higher values of Kd could be explained by the different 
temperature conditions used in each assay and the need of high concentration of the 
enzyme, which make obtaining Kd lower than a half of this concentration hard. In 
addition, it was difficult to distinguish the Tm shifts of Mafenide HCl (µM potent 
drug) a possible factor could be its low solubility at high concentration.  
Summing up the results, it can be concluded that kinetic analysis is more 
sensitive technique, doable and requires lower amount of the enzyme to measure drug 
affinity than FTSA. More experiments will be needed to verify whether various 
modifications of the FTSA approach (like using different buffers or salts) can predict 
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